Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on ProMedicus.
RELATED STOCKHEAD STORIES
Health & Biotech
ScoPo’s Powerplays: Who fancies a ‘MedWalk intervention’? Oh, and ASX healthcare stocks can’t catch a break
News
ASX Large Caps: ASX drops further on war concerns, Treasury Wine rallies on China news
Health & Biotech
ASX Health Stocks: Chimeric leaps 65pc on Phase1A results, Immutep over 12pc on Phase 2
News
CSL, Pro Medicus, Goodman Group. Which other ASX stocks have brokers upgraded?
Health & Biotech
From wine to $8.75 billion success story, Pro Medicus is embracing AI after 40 years at forefront of medical imaging
News
Closing Bell: Local markets fall on timid Tuesday but Biotron bets build as investors ask if it’s aced an anti-viral AIDS therapy
News
ASX Large Caps: Stocks at two-month low, ProMedicus surges 11pc, and Morningstar upgrades coal stocks
News
ASX Small Caps Lunch Wrap: Which tiny town had to call the cops on the cops last week?
Health & Biotech
ScoPo’s Powerplays: CSL, Cochlear drag ASX health sector up in mixed start to reporting season
News
ASX Large Caps: Local bourse up as China cuts key rate; aftermarket stock GUD top gainer, up by 15pc
News
ASX Earnings Wrap: Reckon jumps 13pc; Pro Medicus keeps delivering, up almost 40pc this year
Health & Biotech
ScoPo’s Powerplays: Mesoblast sinks Health sector, and how to live 24 years longer
Health & Biotech
ASX Health Stocks: Pro Medicus nabs $24m, 7-year deal with world renowned cancer hospital
Health & Biotech
ScoPo’s (actually Iain’s) Powerplays: ASX health stocks fall as CSL faces FX headwinds
Health & Biotech
4D Medical’s technology disrupts century-old procedures AND makes over 90pc profit margin
Experts
CRITERION: This ASX biotech is the sole dedicated player in a new $420 billion market
Director Trades
